Replies to post #733584 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

From the 10Q---If this was brought up previously I missed it-in bold.

And maybe this:

The parties are now evaluating the results and developing plans for further experiments.

So not yet done.

[flipper44]

Eureka! On second thought, I think the 10Q section you highlighted is more likely talking about hyperactivating DCVax-L and DCVax-Direct with inflammation-activating lipid. https://patents.justia.com/patent/20240122975

Here our some examples:
oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (oxPAPC), 1-palmityl-2-arachidonyl-sn-glycero-3-phosphoryicholine (PAPC), 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC), and 1-palmitoyl-2-[5-oxovaleroyl]-sn-glycero-3-phosphorylcholine (POV-PC), and species of oxPAPC (e.g., 1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenedioyl) sn-glycero-3-phosphocholine (HOdiA-PC), 1-palmitoyl-2-(5-keto-6-octene-dioyl)-sn-glycero-3-phosphocholine (KOdiA-PC), 1-palmitoyl-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-glycero-3-phosphocholine (HOOA-PC), 1-palmitoyl-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine (KOOA-PC).

It appears there are several companies we might have scanned to pick the one we are working with now.

Remember how excited I was two or three years back about our new hyperactivated dendritic cell patent application?
https://patents.justia.com/patent/20240122975

(Note: we probably in-licensed one filed just after ours as well, imo) (This patent application will almost certainly protect us for ALL cancer indication until 2039 for both DCVax-Direct and DCVax-L.)

Hyperactive dendritic cells display enhanced ability to migrate to lymph nodes
•
Hyperactive dendritic cells retain inflammasome activity in the dLN
•
Hyperactive cDC1s induce long-lived CD8+ T-cell-mediated anti-tumor immunity
•
Hyperactivating stimuli eradicate tumors that are resistant to anti-PD1 therapy
https://www.sciencedirect.com/science/article/pii/S221112472031370X

Long and short of this. In my opinion, this is exactly why we changed course to rapid tumor shrinkage endpoints for many anticipated clinical trials!

The “Booster” inflammatory activating lipid can be used in both DCVax-l and DCVax-Direct production.

What’s truly amazing is that tumor eradication is not the best thing about hyperactivated dendritic cells. What’s really amazing is the durable immune memory they create.

This, as I said a few years ago, is next level stuff, but NWBO’s slow pace since then made me completely miss what they had/are secretly developed/developing with hyperactivated DCVax products then subtly announced in their latest 10q! Imo.

This is huge. It also explains why we are putting our DCVax-Direct program back on line, because this booster agent takes care of all the critical attacks against DCVax Direct, and instead will make tumor response and immune durability its strongest points.

The work is being done in vitro utilizing Eden as the in vitro vessel, imo, because flaskworks is the one engaged in the experiments. Remember, this 10Q section is separate but adjacent to the restart of the DCVax-Direct program.

No wonder LP was talking about massive hiring to come. We must have a BP alignment to announce very soon. IMO.